ARCHIVES

Phase III Trebananib Trial Fails OS Endpoint In Recurrent Platinum-Resistant Ovarian Cancer

This article is from The Cancer Letter archive.

Vol. 37 No. 11 | November 28, 2014

Download PDF Visit The Full Archive

Related Articles

NCI Offers 200 Cell Lines to Scientist

May 6, 1983

Herceptin Lowers Recurrence In Early Breast Cancer

November 25, 2005

TJU Wins NCI Renewal Of Kimmel Center Core Grant; 11 NY Centers Testing Spiral CT.

July 13, 2001

Gavel Changes Hands At NCAB, Korn advises New Members On Role

February 8, 1991

Antman Is President Elect; Minorities More Likely To Get Worse Care, IOM Finds

April 12, 2002

Grant Supplements, and Challenge Grants

February 20, 2009